[go: up one dir, main page]

NO994903L - Behandling eller profylakse av prostatakreft og benign prostatahyperplasi med selektive östrogenreseptormodulatorer - Google Patents

Behandling eller profylakse av prostatakreft og benign prostatahyperplasi med selektive östrogenreseptormodulatorer

Info

Publication number
NO994903L
NO994903L NO994903A NO994903A NO994903L NO 994903 L NO994903 L NO 994903L NO 994903 A NO994903 A NO 994903A NO 994903 A NO994903 A NO 994903A NO 994903 L NO994903 L NO 994903L
Authority
NO
Norway
Prior art keywords
prophylaxis
estrogen receptor
selective estrogen
treatment
prostate cancer
Prior art date
Application number
NO994903A
Other languages
English (en)
Other versions
NO994903D0 (no
Inventor
Blake Lee Neubauer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO994903D0 publication Critical patent/NO994903D0/no
Publication of NO994903L publication Critical patent/NO994903L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for behandling eller profylakse av benign prostatahyperplasi eller prostatakreft hos en pasient som trenger slik behandling som innbefatter administrering av en selektiv østrogenreseptor- moduleringsforbindelse med formel (I), hvori R' og R^ uavhengig er hydroksy og alkoksy med 1 til 4 karbonatomer; og R' og R" er uavhengig metyl eller etyl, eller R' og R'', sammen med nitrogenatomet som de er bundet til danner en pyrrolidino, metyl- pyrrolidino, dimetylpyrrolidino, piperidino, morfolino eller heksametylenimino ring.
NO994903A 1997-04-09 1999-10-08 Behandling eller profylakse av prostatakreft og benign prostatahyperplasi med selektive östrogenreseptormodulatorer NO994903L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4322397P 1997-04-09 1997-04-09
PCT/US1998/007274 WO1998045288A1 (en) 1997-04-09 1998-04-07 Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators

Publications (2)

Publication Number Publication Date
NO994903D0 NO994903D0 (no) 1999-10-08
NO994903L true NO994903L (no) 1999-12-09

Family

ID=21926126

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994903A NO994903L (no) 1997-04-09 1999-10-08 Behandling eller profylakse av prostatakreft og benign prostatahyperplasi med selektive östrogenreseptormodulatorer

Country Status (16)

Country Link
EP (1) EP0975629A4 (no)
JP (1) JP2001518900A (no)
KR (1) KR20010006218A (no)
CN (1) CN1259944A (no)
AU (1) AU6966198A (no)
BR (1) BR9808515A (no)
CA (1) CA2286204A1 (no)
EA (1) EA199900914A1 (no)
HU (1) HUP0003589A3 (no)
ID (1) ID24358A (no)
IL (1) IL132277A0 (no)
NO (1) NO994903L (no)
PL (1) PL336205A1 (no)
TR (1) TR199902701T2 (no)
WO (1) WO1998045288A1 (no)
ZA (1) ZA982819B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
EP1392304A1 (en) * 2001-05-10 2004-03-03 Cedars Sinai Medical Center Use of benzothiophenes to treat and prevent prostate cancer
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
US7825107B2 (en) * 2006-05-22 2010-11-02 Hormos Medical Ltd. Method of treating men suffering from chronic nonbacterial prostatitis with SERM compounds or aromatase inhibitors
EA022760B1 (ru) 2007-10-16 2016-02-29 Репрос Терапьютикс Инк. Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
AU2013225869B2 (en) 2012-02-29 2017-06-08 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
MA38325B1 (fr) 2013-02-19 2019-03-29 Novartis Ag Dérivés de benzothiophène et compositions correspondantes en tant qu'agents de dégradation sélectifs des récepteurs des œstrogènes
JP7048505B2 (ja) 2015-11-10 2022-04-05 パラクリン セラピューティクス エービー Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429922A (en) * 1988-03-09 1995-07-04 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for distinguishing virulent and non-virulent toxoplasma infections
JP3989569B2 (ja) * 1995-02-28 2007-10-10 イーライ リリー アンド カンパニー ベンゾチオフェン化合物、中間体、組成物および方法
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Also Published As

Publication number Publication date
PL336205A1 (en) 2000-06-05
AU6966198A (en) 1998-10-30
ID24358A (id) 2000-07-13
HUP0003589A3 (en) 2002-02-28
EP0975629A4 (en) 2001-03-21
JP2001518900A (ja) 2001-10-16
CA2286204A1 (en) 1998-10-15
WO1998045288A1 (en) 1998-10-15
NO994903D0 (no) 1999-10-08
EP0975629A1 (en) 2000-02-02
ZA982819B (en) 1999-10-04
IL132277A0 (en) 2001-03-19
BR9808515A (pt) 2001-06-19
KR20010006218A (ko) 2001-01-26
EA199900914A1 (ru) 2000-04-24
HUP0003589A2 (hu) 2002-01-28
TR199902701T2 (xx) 2000-02-21
CN1259944A (zh) 2000-07-12

Similar Documents

Publication Publication Date Title
NO994901L (no) Behandling av sentralnerveforstyrrelser ved selektive östrogenreseptormodulatorer
NZ332762A (en) Isobutylgaba and its derivatives for the treatment of pain
MY125942A (en) Aminoalkoxy carbazoles for the treatment of cns diseases
ATE283271T1 (de) Porphyrin derivate, ihre verwendung in der photodynamischen therapie und diese enthaltende medizinische geräte
BR9807674A (pt) Inibidores bicìclicos da proteìna farnesil transferase
AU565185B2 (en) N-phenylbenzamide derivatives
AU6350699A (en) Chemical compounds
NO994903L (no) Behandling eller profylakse av prostatakreft og benign prostatahyperplasi med selektive östrogenreseptormodulatorer
WO2001081340A3 (en) Heterocycles that are inhibitors of impdh enzyme
NZ313185A (en) 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
ATE156839T1 (de) Neue delta-17 und delta-20 ungesätigte und gesatigte 17--g(b)-substituierte-4-aza-5-g(a)- androstan-3-on verbindungen als inhibitoren von 5-alpha-reductase
BR0011865A (pt) derivados aromáticos e heterocìclicos de fitoteróis e/ou fitostanóis para uso no tratamento e prevenção de doença cardiovascular
DE69713273D1 (de) Verwendung von 3,4-Diphenylchromanen zur Herstellung eines Arzneimittels zur Behandlung bzw. Vorbeugung des Prostatakarzinoms
IL136735A0 (en) Substituted 2-benzylamino-2-phenyl-acetamide compounds
NO20002371L (no) 2-Arylbenzo[b]tiofener til behandling av østrogen- deprivasjonssyndrom
NO994902L (no) Forebygging av brystkreft ved selektive östrogenreseptormodulatorer
ATE22294T1 (de) Pyrido(3,4-c)psoralene, herstellung, verwendung in der kosmetologie und als arzneimittel und diese enthaltende zubereitungen.
AU2002211493A1 (en) Indole derivatives as pde5-inhibitors
YU46302A (sh) Supstituisani piroli
NZ502537A (en) Androst-1-en-3-one derivatives and pharmaceutical formulations thereof; useful for the treatment of alopecia, female hirsutism, seborrhea, and useful for the prevention of bone metastasis caused by prostatic cancer
NZ337048A (en) Use of N-[1-methyl-(substituted phenyl)ethyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide derivatives to treat prostate cancer
IL133392A0 (en) Benzo (5, 6) cyclohepta (1, 2b) pyridine derivatives useful for inhibition of farnesyl protein transferase
MXPA98005355A (es) Derivados de 5-[(heteroaril) alquil]-3 -oxo-pirido [1, 2-a]bencimidazol -4-carboxamida utiles en el tratamiento de trastornos del sistema nervioso central.
MX9706086A (es) Preparaciones farmaceuticas para inhibicion de tnf.
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application